Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Relapsing Multiple Sclerosis
Clinical trial register · United Kingdom · industry-sponsored

Relapsing Multiple Sclerosis Trials in the UK, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2859 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 03 Oct 2026, 03:15 UTC
2859
Studies in scope
industry-sponsored, all four open statuses
1382
Recruiting now
open to new participants
541
Lead sponsors
across recruiting studies
Top sites
London 5 Swansea 3 Glasgow 2 Sheffield 2 Oxford 2
Narrow the registerReset
Recruitment status
Phase
Site city
London5 Swansea3 Glasgow2 Sheffield2 Oxford2
All 18 cities
Target enrolment
to

Relapsing Multiple Sclerosis trials in the UK

8 of 2859 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
400
Sheffield, Leeds, London, Swansea
2025-06-23
Active, closed
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311Relapsing Multiple Sclerosis
Zenas BioPharma (USA), LLC
Phase 2
93
Leicester, London, Swansea
2024-08-26
Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
NCT06433752Relapsing Multiple Sclerosis, Multiple Sclerosis
TG Therapeutics, Inc.
Observational
2,000
London
2024-07-22
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Sanofi
Phase 3
2,500
Exeter, Kent, London, Swansea, Nottingham, Oxford, Cardiff, Bristol
2024-04-16
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
NCT05147220Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,000
Westbruy on Trym, Winchester, Glasgow
2021-12-16
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
NCT05156281Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,007
Inverness, Canterbury
2021-12-13
Active, closed
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586023Relapsing Multiple Sclerosis
Hoffmann-La Roche
Phase 3
751
Salford
2021-03-24
Active, closed
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,882
Luton, Glasgow, Sheffield, London, Oxford
2018-12-28
Rows per page Showing 1–8 of 8
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 3 October 2026. https://priyalifescience.com/clinical-trials-uk/condition/relapsing-multiple-sclerosis

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,859 studies in total at the last sync on 03 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 8 of those studies listing the condition Relapsing Multiple Sclerosis.

How many Relapsing Multiple Sclerosis trials are recruiting in the UK?

2 of the 8 studies on this page are recruiting new participants as of the 03 Oct 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 6 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Relapsing Multiple Sclerosis), 8 studies
PhaseStudiesRecruitingShare
Phase 36175%
Observational1112.5%
Phase 21012.5%

Most active sponsors

Lead sponsors with the most studies (Relapsing Multiple Sclerosis)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals41
Hoffmann-La Roche10
Sanofi10
TG Therapeutics, Inc.11
Zenas BioPharma (USA), LLC10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.